AR107261A1 - Vacuna marcadora de pestivirus - Google Patents

Vacuna marcadora de pestivirus

Info

Publication number
AR107261A1
AR107261A1 ARP160104074A ARP160104074A AR107261A1 AR 107261 A1 AR107261 A1 AR 107261A1 AR P160104074 A ARP160104074 A AR P160104074A AR P160104074 A ARP160104074 A AR P160104074A AR 107261 A1 AR107261 A1 AR 107261A1
Authority
AR
Argentina
Prior art keywords
pestivirus
erns gene
mutant
chimeric
gene
Prior art date
Application number
ARP160104074A
Other languages
English (en)
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of AR107261A1 publication Critical patent/AR107261A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation
    • C12N2770/24362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Pestivirus mutante que tiene un genoma en donde el gen Erns está mutado, caracterizado porque el gen Erns mutado es un gen Erns quimérico, y el gen Erns quimérico se compone de una parte 5’ y una parte 3’, en donde la parte 5’ representa 60 - 95% del gen Erns quimérico, y la parte 3’ representa el resto del gen Erns quimérico, y en donde dicha parte 5’ se compone de la parte correspondiente de un gen Erns de un Pestivirus que es genéticamente distante del Pestivirus mutante, y en donde dicha parte 3’ se compone de la parte correspondiente de un gen Erns de un Pestivirus que es genéticamente cercano al Pestivirus mutante. Reivindicación 8: Método para la construcción de un Pestivirus mutante de acuerdo con cualquiera de las reivindicaciones 1 - 7, dicho método comprende la mutación del gen Erns de un genoma de Pestivirus, en un gen Erns quimérico como se define en la reivindicación 1. Reivindicación 10: Vacuna para animales que comprende un Pestivirus mutante de acuerdo con cualquiera de las reivindicaciones 1 - 7, o una célula huésped de acuerdo con la reivindicación 9, o cualquier combinación de las mismas, y un portador farmacéuticamente aceptable. Reivindicación 20: Kit de pruebas de diagnóstico que comprende un Pestivirus mutante de acuerdo con cualquiera de las reivindicaciones 1 - 7, o una proteína Erns quimérica expresada por el Pestivirus mutante. Reivindicación 21: Un método para controlar una infección con un Pestivirus en una población de animales del orden Artiodactyla, por el uso combinado de una vacuna de acuerdo con la reivindicación 10 y un kit de pruebas de diagnóstico de acuerdo con la reivindicación 20.
ARP160104074A 2015-12-30 2016-12-29 Vacuna marcadora de pestivirus AR107261A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15203202 2015-12-30

Publications (1)

Publication Number Publication Date
AR107261A1 true AR107261A1 (es) 2018-04-11

Family

ID=55085493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160104074A AR107261A1 (es) 2015-12-30 2016-12-29 Vacuna marcadora de pestivirus

Country Status (11)

Country Link
US (1) US20190240311A1 (es)
EP (1) EP3397280A1 (es)
JP (1) JP2019506850A (es)
CN (1) CN108430504A (es)
AR (1) AR107261A1 (es)
AU (1) AU2016382839A1 (es)
BR (1) BR112018013400A2 (es)
CA (1) CA3006921A1 (es)
MX (1) MX2018008085A (es)
RU (1) RU2018127402A (es)
WO (1) WO2017114778A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018110208A1 (de) * 2018-04-27 2019-10-31 Stiftung Tierärztliche Hochschule Hannover Gentechnisch veränderte Pestiviren und deren Verwendung als Markerimpfstoff
JP6976621B1 (ja) * 2021-02-04 2021-12-08 株式会社Icst 検査器具、検査キットおよび検査方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1174506A1 (en) * 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek C-terminal Erns peptide and analogues thereof
AU2009323784B2 (en) * 2008-12-03 2013-08-15 Zoetis Services Llc Bovine viral diarrhea virus with a modified Erns protein
BR112014004261B8 (pt) * 2011-08-24 2022-11-08 Zoetis Llc Diagnósticos de vacina melhorada
EP2890707A1 (en) * 2012-08-29 2015-07-08 Intervet International B.V. Marker vaccine

Also Published As

Publication number Publication date
RU2018127402A (ru) 2020-01-30
EP3397280A1 (en) 2018-11-07
JP2019506850A (ja) 2019-03-14
MX2018008085A (es) 2018-08-23
RU2018127402A3 (es) 2020-01-30
AU2016382839A1 (en) 2018-06-21
BR112018013400A2 (pt) 2018-12-18
CN108430504A (zh) 2018-08-21
WO2017114778A1 (en) 2017-07-06
US20190240311A1 (en) 2019-08-08
CA3006921A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
BR112019010565A2 (pt) aplicação viral de neoantígenos
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
EA201792663A1 (ru) Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
ECSP18083561A (es) Proteínas de fusión gdf15 y usos de estas
BR112015002280A2 (pt) produção de gado resistente a vfa por substituição de alelo
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
BR112015024605A2 (pt) sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
EA201890137A1 (ru) Среда для культивирования клеток с добавлением таурина и способы применения
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
BR112017005378A2 (pt) composições que compreendem células recombinantes de bacillus e um outro agente de controle biológico.
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
BR112016007727A2 (pt) célula hospedeira, métodos para produzir um glicoconjugado, uma célula hospedeira e uma proteína n-glicosilada, para tratar ou prevenir uma infecção em um indivíduo e para induzir uma resposta imune em um indivíduo, glicoconjugado, kit, e, plasmídeo isolado
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
BR112017005509A2 (pt) composições que compreendem células recombinantes de bacillus e um outro agente de controle biológico.
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
EA202091349A1 (ru) Способы культивирования клеток
AR113812A1 (es) Estrategias para precisión en la edición del genoma
BR112018009097A8 (pt) spodoptera frugiperda resistente a vip3a
SG11202009389QA (en) Use of nw_003613638.1 in cho cell genome for stable expression of protein
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure